Todd is an accomplished operating executive and entrepreneur, having served as Citigroup CFO for 5 years and as CEO of Citigroup’s $10 Billion Global Wealth Management division for 2.5 years. Todd is a leading practitioner on M&A and business strategy, having led the acquisition and strategy efforts for Citigroup and GE Capital, as well as serving as advisor to Fortune 500 firms while at Bain & Co., Booz Allen Hamilton, and Barents Group. He has extensive investing experience as CEO of Citigroup Alternative investments, Chairman of the Citi Pension investment Committee, Chairman of the Dynasty Investment Committee, and a member of the Investment Committees for the Davidson College and World Resources Institute endowments.
Just prior to joining Kairos, Todd has been Co-Founder and Chairman of Dynasty Financial Partners, the leading investment and technology platform for sophisticated independent advisors. Founded by Todd and his colleagues in 2010, Dynasty serves nearly 50 RIA firms nationally, with $50 billion under management. In addition to serving as Chairman, Todd has served in several operating roles since the firm’s founding, including Chairing the Investment Committee, serving as CIO, and designing and leading Dynasty Capital Strategies.
Todd received his MBA with Distinction from the Wharton School of Business and his BA in Economics from Davidson College.
What is Todd S. Thomson's net worth?
The estimated net worth of Todd S. Thomson is at least $800.74 thousand as of January 5th, 2026. Mr. Thomson owns 904,795 shares of Actuate Therapeutics stock worth more than $800,744 as of October 1st. This net worth approximation does not reflect any other assets that Mr. Thomson may own. Learn More about Todd S. Thomson's net worth.
How do I contact Todd S. Thomson?
Has Todd S. Thomson been buying or selling shares of Actuate Therapeutics?
Todd S. Thomson has not been actively trading shares of Actuate Therapeutics over the course of the past ninety days. Most recently, Todd S. Thomson sold 280,000 shares of the business's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $5.80, for a transaction totalling $1,624,000.00. Following the completion of the sale, the director now directly owns 904,795 shares of the company's stock, valued at $5,247,811. Learn More on Todd S. Thomson's trading history.
Who are Actuate Therapeutics' active insiders?
Are insiders buying or selling shares of Actuate Therapeutics?
In the last twelve months, insiders at the sold shares 1 times. They sold a total of 280,000 shares worth more than $1,624,000.00. The most recent insider tranaction occured on January, 5th when Director
Todd S. Thomson sold 280,000 shares worth more than $1,624,000.00. Insiders at Actuate Therapeutics own 58.0% of the company.
Learn More about insider trades at Actuate Therapeutics. Information on this page was last updated on 1/5/2026.
